CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

被引:5
|
作者
Yi, Yonglin [1 ]
Qiu, Zhengang [2 ]
Yao, Zifu [1 ,3 ]
Lin, Anqi [1 ]
Qin, Yimin [1 ]
Sha, Ruizhan [1 ]
Wei, Ting [1 ]
Wang, Yanru [1 ]
Cheng, Quan [4 ]
Zhang, Jian [1 ]
Luo, Peng [1 ]
Shen, Weitao [1 ]
机构
[1] Southern Med Univ, Zhujiang Hosp, Dept Oncol, Guangzhou, Peoples R China
[2] Gannan Med Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Peoples R China
[3] Southern Med Univ, Clin Med Sch 1, Guangzhou, Peoples R China
[4] Ctr South Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Peoples R China
来源
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2022年 / 9卷
基金
中国国家自然科学基金;
关键词
small cell lung cancer; CAMSAP1; platinum-based chemotherapy; drug sensitivity; biomarker; ACTIVATED PROTEIN-KINASE; TGF-BETA; B-CELLS; EXPRESSION; CHEMORESISTANCE; IMMUNOTHERAPY; SURVIVAL; FAMILY; MECHANISMS; MANAGEMENT;
D O I
10.3389/fcell.2021.770811
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Platinum-based chemotherapy is the first-line treatment for small cell lung cancer (SCLC). However, due to patients developing a resistance to the drug, most experience relapse and their cancer can become untreatable. A large number of recent studies have found that platinum drug sensitivity of various cancers is affected by specific gene mutations, and so with this study, we attempted to find an effective genetic biomarker in SCLC patients that indicates their sensitivity to platinum-based drugs. To do this, we first analyzed whole exome sequencing (WES) and clinical data from two cohorts to find gene mutations related to the prognosis and to the platinum drug sensitivity of SCLC patients. The cohorts used were the Zhujiang cohort (N = 138) and the cohort reported by George et al. (N = 101). We then carried out gene set variation analysis (GSVA) and gene set enrichment analysis (GSEA) to investigate possible molecular mechanisms through which these gene mutations affect patient prognosis and platinum drug sensitivity. We found that for SCLC patients, CAMSAP1 mutation can activate anti-tumor immunity, mediate tumor cell apoptosis, inhibit epithelial-mesenchymal transition (EMT), improve prognosis, and improve platinum drug sensitivity, suggesting that CAMSAP1 mutation may be a potential biomarker indicating platinum drug sensitivity and patient prognosis in SCLC.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Curative efficacy might be an early predictor of prognosis in patients with small cell lung cancer treated with 2 cycles of platinum-based first-line chemotherapy
    Zhu, Kaibo
    Jiang, Minlin
    Xu, Yi
    Chen, Peixin
    Wang, Hao
    Yu, Jia
    Zhu, Jun
    Zhao, Wencheng
    Meng, Die
    He, Yayi
    JOURNAL OF THORACIC DISEASE, 2021, 13 (02) : 1205 - 1214
  • [32] Chemotherapy-induced leukopenia as a prognostic factor in patients with metastatic non-small cell lung cancer treated with platinum-based chemotherapy
    Huang, Aimi
    Ma, Meili
    Jin, Bo
    Han, Baohui
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (02): : 5241 - 5248
  • [33] The Association Between Genetic Polymorphisms of Transporter Genes and Prognosis of Platinum-Based Chemotherapy in Lung Cancer Patients
    He, Jia
    Wang, Zhan
    Zou, Ting
    Wang, Ying
    Li, Xiang -Ping
    Chen, Juan
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2022, 15 : 817 - 825
  • [34] ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer
    Barba, Andres
    Lopez-Vilaro, Laura
    Ferre, Malena
    Majem, Margarita
    Martinez-Recio, Sergio
    Bell, Olga
    Arranz, Maria J.
    Salazar, Juliana
    Sullivan, Ivana
    PHARMACEUTICS, 2024, 16 (09)
  • [35] Association of variations in the Fanconi anemia complementation group and prognosis in Non-small cell lung cancer patients with Platinum-based chemotherapy
    Mo, Jun-Luan
    Liu, Jia-Si
    Xiao, Qi
    Hong, Wen-Xu
    Yin, Ji-Ye
    Chen, Juan
    Liu, Zhao-Qian
    GENE, 2022, 825
  • [36] Overexpression of MAC30 is Resistant to Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer
    Chen, Ruhua
    Fen, Yan
    Lin, Xubo
    Ma, Tieliang
    Cai, Hourong
    Ding, Hui
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2016, 15 (06) : 815 - 820
  • [37] Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation
    Tanaka, Ichidai
    Morise, Masahiro
    Miyazawa, Ayako
    Kodama, Yuta
    Tamiya, Yutaro
    Gen, Soei
    Matsui, Akira
    Hase, Tetsunari
    Hashimoto, Naozumi
    Sato, Mitsuo
    Hasegawa, Yoshinori
    CLINICAL LUNG CANCER, 2020, 21 (03) : 273 - +
  • [38] Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy
    Vassalou, Helen
    Stathopoulos, Efstathios
    Fiolitaki, Georgia
    Koutsopoulos, Anastasios
    Voutsina, Alexandra
    Georgoulias, Vassilis
    Mavroudis, Dimitris
    LUNG CANCER, 2013, 82 (02) : 324 - 329
  • [39] Vitamin D deficiency is associated with a poor prognosis in advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy
    Ma, Kewei
    Xu, Wang
    Wang, Chang
    Li, Biao
    Su, Keju
    Li, Wei
    CANCER BIOMARKERS, 2017, 18 (03) : 297 - 303
  • [40] Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy
    Grossi, Francesco
    Genova, Carlo
    Rijavec, Erika
    Barletta, Giulia
    Biello, Federica
    Dal Bello, Maria Giovanna
    Meyer, Krista
    Roder, Joanna
    Roder, Heinrich
    Grigorieva, Julia
    LUNG CANCER, 2018, 117 : 64 - 69